GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19

 GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19

GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19

Shots:

  • The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 in 583 adults at high risk of hospitalization
  • The study demonstrated an 85% reduction in hospitalization. Due to evidence of profound efficacy, IDMC recommended stopping the trial for further enrollment
  • Preclinical data of VIR-7831 suggested that the mAB maintains its activity against emerging variants. Additionally, the companies will continue discussions with the EMA and other global regulators to make VIR-7831 available to patients with COVID-19 asap

Click here ­to­ read full press release/ article | Ref: GSK | Image: Financial Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post